Latest News

Researchers optimize aptamer with enhanced myelin-binding properties for multiple sclerosis treatment

A new study has demonstrated the enhanced ability of an optimized 20-nucleotide derivative of a larger DNA aptamer to bind myelin in a mouse model of multiple sclerosis. The study, which also provides the first evidence of cross-reactivity of this myelin-binding aptamer with human brain cells, is published in Nucleic Acid Therapeutics.

Source link

Related posts

STAT Plus: Glaxo revamps sales rep compensation as part of an effort to compete in the cancer market


Medical News Today: How strangers judge personality based on body shape


Geriatrics experts on gender equity in health care: 'When women rise, we all rise'


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World